Exousia Bio Reports No Revenue and Increased Losses Following Acquisition of Exousia AI

Exousia Bio, Inc., formerly known as L A M Y, reported its financial results for the six months ending November 30, 2025, revealing a significant shift in its business operations following the acquisition of Exousia AI. The company generated no revenue during this period, a decline from $3,750 reported in the same period last year. The absence of revenue reflects the transition from its previous business model focused on educational platforms to a new strategy centered on biotechnology, specifically the therapeutic potential of exosomes in oncology.

The company's operating expenses surged to $206,711 for the six months ended November 30, 2025, compared to $10,632 in the prior year. This increase is attributed to costs associated with the acquisition and the initial stages of developing its new business plan. Exousia Bio reported a net loss of $50,897 for the current period, contrasting sharply with a net profit of $80,659 in the previous year. The financial results also included other income of $217,922, primarily from a gain on the acquisition of Exousia AI.

In terms of operational changes, Exousia Bio underwent a significant management overhaul following the acquisition, with Matthew Dwyer appointed as the new Sole Officer and Director. The company issued 62,223,000 shares of common stock to facilitate the acquisition, increasing the total shares outstanding to 70,000,000 as of November 30, 2025. The company’s total assets were reported at $22,050,670, primarily consisting of intangible assets related to Exousia AI, while total liabilities stood at $261,023.

Looking ahead, Exousia Bio faces challenges in establishing a sustainable revenue stream and managing its accumulated deficit of $288,623. The company has indicated that it will require additional capital to support its operations and pursue its new business strategy. Management plans to seek funding through equity and debt financing, although there are no guarantees of success in securing the necessary resources. The company’s ability to continue as a going concern remains uncertain, as it has not yet established a reliable source of revenue to cover its operating costs.